Study Title

68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study in Patients With Various Cancers

Study Details

Description:

68Ga-JH12 is a novel radiotracer targeting C-X-C motif chemokine receptor 4 (CXCR4). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH12 in patients with different types of cancer.

Sponsor:

First Affiliated Hospital of Fujian Medical University

Contacts:

Guochang Wang, MD

guochang1007@163.com

+86-0591-87981619

Weibing Miao, MD

miaoweibing@126.com

+86-0591-87981618

Government Study Link:

NCT06688188 - Click here to see study on

ClinicalTrials.gov

Drug Details

68Ga-JH12
Isotope(s):
    GALLIUM-68
    Radioisotope: Ga-68
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 68 minutes
    Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
    Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
    Range: N/A
    Decay Daughters: Zn68 (Stable)
    Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
  • GALLIUM-68
Target(s):
  • CXCR4

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468